THERAPEUTIC MODALITIES Archives - Page 2 of 24

Targeting ER Mutations and Drug Resistance

Targeting ER Mutations and Drug Resistance: R&D Strategies and Comprehensive Preclinical Evaluation of Novel ER Degraders Introduction Estrogen receptor (ER)-positive...

PD-1 Blockade with a DLL3 TCE Potentiates Efficacy in SCLC

Small cell lung cancer (SCLC) remains one of the most aggressive and difficult-to-treat cancers, highlighting the ongoing need for new...

Novel E3 Ligase to Support Targeted Protein Degradation

Targeted protein degradation (TPD) continues to expand the possibilities for next-generation therapeutics, and identifying novel E3 ligases remains an important...

Mechanistic Profiling of ADC-resistant Cancer Cell Lines

Antibody-drug conjugates (ADCs) have emerged as an important modality in targeted cancer therapy development. However, acquired resistance continues to limit...

DEL and Display Technologies Empower Discovery of Peptide Drugs

In recent years, peptide-based therapeutics have emerged as a significant class of drugs in the pharmaceutical landscape, offering numerous advantages,...

Supporting Discovery of mRNA Drugs

Unlike conventional protein-targeted therapies, which often provide only transient effects, nucleic acid therapeutics have the potential for long-lasting effects and...

Advanced Conjugate Delivery Systems for Oligonucleotides

Oligonucleotide therapeutics represent a transformative treatment modality with demonstrated potential across metabolic disorders, CNS diseases, muscular dystrophies, and a broad...

Peptide Early Discovery Services

Peptide drugs, composed of short chains of amino acids, represent a promising class of therapeutics with unique advantages over traditional...

mTOR Inhibition Enhances Targeted Protein Degradation Efficacy

Targeted protein degradation (TPD) approaches, including molecular glue degraders (MGDs) and proteolysis targeting chimeras (PROTACs), can overcome traditional occupancy-based inhibitor...

Knowledge Library